Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Notice of Annual General
Meeting
Oncimmune Holdings plc (AIM: ONC.L), a leading
autoantibody profiling company to the pharmaceutical and
biotechnology industry enabling precision medicine, today announces
that the Notice of Annual General Meeting ("AGM") has been sent to
shareholders.
The AGM will be held on 27 February 2025 at
10:30 a.m. at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y
0DT.
The Notice of AGM has been sent to shareholders
and can also be viewed on the "Investors" section of the Company's
website at www.oncimmune.com.
The audit process for the Company's financial
results for the 12 months ended 31 August 2024 ("FY2024") is
continuing in the ordinary course and the Company expects its
annual report, including the financial statements for FY2024, to be
published by the end of February 2025 and for this to be laid
before a separate general meeting.
For further
information:
contact@oncimmune.com
Cavendish
Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist
Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK,
with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com
